Gossamer Bio is a technology company.
Gossamer Bio has raised $330.0M across 2 funding rounds.
Gossamer Bio has raised $330.0M in total across 2 funding rounds.
Gossamer Bio has raised $330.0M in total across 2 funding rounds.
Gossamer Bio's investors include ARCH Venture Partners, Cure Ventures.
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an inhaled inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, delivered via dry powder inhaler for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).[1][2][3] Headquartered in San Diego, California, it serves patients with these rare diseases by aiming to enhance their lives through innovative therapies, while operating as a publicly traded entity with a global workforce and a cloud-first tech strategy that includes robust cybersecurity measures.[1][4] The company focuses on late-stage clinical development and potential commercialization of seralutinib, addressing unmet needs in rare pulmonary conditions.[3][4]
Gossamer Bio emerged as a biopharmaceutical innovator centered on rare disease treatments, with its name symbolizing the fragile yet vital connections in relationships—reflecting commitments to patients, employees, shareholders, providers, and partners.[1] While specific founders are not detailed in available sources, the company established itself as a clinical-stage player headquartered in San Diego, advancing seralutinib through development phases for PAH and PH-ILD.[1][4] Key early traction includes positioning as a late-stage clinical biopharmaceutical firm, with a focus on inhaled therapies, and implementing advanced security operations to support its cloud-first infrastructure amid global operations.[3][4]
Gossamer Bio rides the wave of precision medicine and inhaled drug delivery innovations in biopharma, targeting rare pulmonary diseases amid growing demand for therapies in PAH and PH-ILD where current treatments fall short.[1][2] Timing aligns with advances in kinase inhibitors and dry powder inhalers, fueled by market forces like rising rare disease awareness, regulatory incentives for orphan drugs, and biopharma's shift to cloud-native operations for faster R&D.[4] It influences the ecosystem by exemplifying how cybersecurity integration secures IP in a cloud-first model, potentially setting benchmarks for lean security in clinical-stage biotechs handling sensitive data.[4]
Gossamer Bio's trajectory hinges on seralutinib's clinical milestones, with potential FDA pathways for PAH and PH-ILD approvals driving commercialization and revenue.[1][3] Trends like AI-enhanced drug discovery, expanded rare disease funding, and zero-trust cybersecurity will shape its path, enabling efficient scaling amid global trials and partnerships.[2][4] Its influence may grow by pioneering inhaled therapies that improve patient outcomes, reinforcing biopharma's tech-biotech convergence—ultimately strengthening those vital "gossamer threads" with patients and stakeholders.[1]
Gossamer Bio has raised $330.0M across 2 funding rounds. Most recently, it raised $230.0M Series B in July 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2018 | $230.0M Series B | ARCH Venture Partners, Cure Ventures | |
| Jan 1, 2018 | $100.0M Series A | ARCH Venture Partners, Cure Ventures |